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S U M M A R Y
While infections caused by Enterococcus faecium resistant to vancomycin (VRE) are increasing, linezolid-
resistant strains are still rare. We present the case of a 10-year-old girl with severe sepsis caused by a
linezolid-resistant E. faecium (Van-B VRE) after multiple trauma and right-sided hemipelvectomy. The
off-label use of a targeted antimicrobial therapy with daptomycin (350 mg/day; approximately 8 mg/kg)
for 17 days resulted in rapid normalization of infection parameters and improved clinical status. No side
effects were observed and the patient was successfully discharged from the intensive care unit.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Over the last decade, the application of vancomycin and other
broad-spectrum antibiotics have led to an increase in infections
with vancomycin-resistant strains of Enterococcus faecium (VRE).1
These strains are commonly treated with linezolid. Despite its
widespread usage, linezolid-resistant strains of E. faecium are still
rare and have been identiﬁed mainly in patients who have
undergone long courses of linezolid therapy before.1,2
2. Case report
We present the case of a 10-year-old girl who suffered from a
rollover trauma by a truck, resulting in an unstable pelvic fracture
with a severe decollement of the right trunk. While undergoing
treatment in a district hospital, the patient received clindamycin
and piperacillin/tazobactam (for Pseudomonas aeruginosa in
tracheal secretion). The girl was transferred to our institution
for further surgical treatment. After admission, the patient
underwent a right-sided hemipelvectomy and negative pressure
wound therapy. Despite continued antibiotic therapy with
piperacillin/tazobactam and clindamycin, the patient became* Corresponding author. Tel.: +49 211 89073769; fax: +49 211 89073085.
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cocci, therefore therapy was changed to linezolid and meropenem.
However, even with this broad antibiotic medication, no clinical
improvement was observed. Further differentiation revealed a
vancomycin-resistant, but teicoplanin-sensitive strain of E. faecium
(Van-B VRE). Additionally, a linezolid resistance was detected. The
minimal inhibitory concentration (MIC) breakpoint for linezolid
was >4 mg/l, both at our institutional site as well as at the
reference laboratory (Robert Koch Institute, Wernigerode,
Germany). The antimicrobial therapy was switched to daptomycin
(350 mg/day; approximately 8 mg/kg), which was continued for 17
days. Due to this targeted therapy, infection parameters normal-
ized and her clinical status improved rapidly. After secondary
wound closure, we were able to transfer the patient to a
rehabilitation center.
3. Discussion
Linezolid, as an oxazolidinone, is bacteriostatic by inhibiting
protein synthesis.3 As it is approved by the US Food and Drug
Administration, linezolid is commonly used to treat VRE infections
worldwide.1 Linezolid resistance remains uncommon, but out-
breaks and dissemination of linezolid-resistant strains have been
reported.2 The LEADER surveillance program, including a total of
61 medical centers in the USA, recovered a total of 934 Enterococcus
species isolates; most were identiﬁed as Enterococcus faecalis (564;ses. Published by Elsevier Ltd. All rights reserved.
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faecalis and 10 E. faecium) had a MIC for linezolid of 4 mg/l,
resulting in an overall linezolid resistance rate of 0.75%. However,
over the past 7 years, no signiﬁcant increase in linezolid resistance
has been observed.4 The most common mechanism of resistance is
mediated by G2576T mutations encoding the 23S rRNA. As E. faecium
has six copies of the RNA genes, it is assumed that the level of
resistance might be associated with the number of mutated alleles.1
Linezolid resistance is thought to occur after prolonged treatment or
inappropriate dosing. In contrast, our case shows that linezolid
resistance might also occur in children and in patients who have
never received this antibiotic drug before, as reported recently.1,2 It
remains unclear whether the linezolid-resistant strain was acquired
from another patient or if the mutation occurred independently.
Following the implementation of routine screening for VRE in our
intensive care unit, we did not identify other patients with
colonization or infections with linezolid-resistant strains.
Daptomycin is not approved for the treatment of VRE infections
and especially not in children.1 In our pediatric patient, the off-
label use of daptomycin was initiated with interdisciplinary
consent and parental approval, resulting in a rapid control of
infection without the observation of any side effects. However, anacquired resistance to daptomycin as well as the underlying
mechanism have been described recently.5 This may limit the
future antibiotic therapy of multiple resistant enterococci.
Therefore, the use of linezolid and daptomycin should be
considered carefully.
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